A detailed history of Schroder Investment Management Group transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 12,607 shares of KRYS stock, worth $2.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,607
Previous 40,380 68.78%
Holding current value
$2.08 Million
Previous $7.42 Million 69.09%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$174.7 - $213.66 $4.85 Million - $5.93 Million
-27,773 Reduced 68.78%
12,607 $2.29 Million
Q2 2024

Aug 12, 2024

BUY
$153.12 - $183.64 $137,195 - $164,541
896 Added 2.27%
40,380 $7.42 Million
Q1 2024

May 14, 2024

SELL
$108.01 - $179.35 $3.83 Million - $6.36 Million
-35,461 Reduced 47.32%
39,484 $7.03 Million
Q4 2023

Feb 13, 2024

BUY
$96.0 - $128.29 $7.19 Million - $9.61 Million
74,945 New
74,945 $9.3 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.23B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.